From algorithm to dialogue: interpreting the 2026 BCLC-CUSE strategy for HCC care

Hepatoma Research

Authors 2

1. Ralf Weiskirchen corresponding
2. Amedeo Lonardo Aachen Correspondence to: Prof. Ralf Weiskirchen Institute of Molecular Pathobiochemistry Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC)

   RWTH Aachen University · Universitätsklinikum Aachen

   Affiliation as printed

   Correspondence to: Prof. Ralf Weiskirchen, Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen D-52074, Germany. E-mail: rweiskirchen@ukaachen.de